DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
Key Highlights
- ➤Corexa Health agreed to commercially supply six peptides recommended by FDA’s advisory committee
- ➤Corexa Pharmacy intends to begin dispensing compliant compounded peptide prescriptions in November 2026
- ➤DataMEDS will use Health Lives Here to collect and report peptide safety data
- ➤DataMEDS will provide bulk drug substance and API logistics through its Lakeland warehouse
- ➤U.S. compounding pharmacy market projected to grow from $18 billion in 2025 to over $31 billion by 2035
Expert Statements
Gerald Commissiong, Interim Co-CEO of DataMEDS
“HHS' recent policy changes allow Corexa Pharmacy to dispense compounded versions of these Six Peptides and also allows our distribution division to leverage its third-party logistics (3PL) capabilities to help bulk drug substance and API to compliantly manage their supply via our strategically located warehouse in Lakeland, Florida.”
Gerald Commissiong, Interim Co-CEO of DataMEDS
“Through relationships with emerging manufacturers of compliant drug substance or API, helping to improve access to the Six Peptides for the 503A compounding pharmacies within our network of 6,500+ independent pharmacies.”
Gerald Commissiong, Interim Co-CEO of DataMEDS
“This represents a significant opportunity for Corexa to give physicians a regulated, pharmacy-compounded option in place of the unregulated research-use-only products sold online.”
Gerald Commissiong, Interim Co-CEO of DataMEDS
“We believe that many gray market patients would prefer to purchase their peptides from a licensed pharmacy.”
TAMPA, FL / ACCESS Newswire / November 2, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company")(NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx(™) artificial intelligence platform and PharmacyChain(™) blockchain-enabled smart contracts platform, today announced that its pharmacy-focused subsidiary Corexa Health has entered into an agreement for commercial supply to bulk drug substance and API of six (6) peptides (BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, together the "Six Peptides") recommended by the U.S. Food and Drug Administration's (FDA) Pharmacy Compounding Advisory Committee (PCAC) at its July 23-24, 2026 meeting. Corexa Pharmacy intends to begin dispending compliant compounded peptide prescriptions for patients in November 2026.
DataMEDS intends to leverage the Health Lives Here mobile application to help collect and report safety data, in accordance with U.S. Health and Human Services' (HHS) Enforcement Discretion Policy (EDP) published in the Federal Register on October 30, 2026. The U.S. compounding pharmacy market is expected to grow from $18 billion in 2025 to over $31 billion by 2035, according to Precedence Research.
Get started
Create a free account to read the full story.